Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ADAM7-AS1 is a long non-coding antisense RNA transcribed from the genomic region overlapping the protein-coding genes ADAM7, ADAMDEC1, and ADAM28. Like other antisense lncRNAs, it is thought to regulate expression of its sense counterparts via base pairing with mRNAs, modulation of chromatin states, or transcriptional interference. While lncRNA antisense transcripts are implicated in diverse biological processes and diseases, there is currently no specific disease or therapeutic relevance directly attributed to ADAM7-AS1 in public domain sources. Its principal function is as a regulator of gene expression, consistent with the general role of antisense lncRNAs. ADAM7-AS1 is not a classical drug target, but a regulatory antisense lncRNA gene, whose primary function is thought to be the modulation of gene expression. No specific aliases, disease associations, drugs, biomarkers, or therapeutic interventions have been described for this target as of now.
For antisense oligonucleotide therapies in general: RNase H-mediated RNA degradation, transcriptional interference, modulation of epigenetic marks, alternative splicing control
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ADAM7, ADAMDEC1 and ADAM28 antisense RNA 1 (ADAM7-AS1).